

Hong Kong Exchanges and Clearing Limited and The Stock Exchange of Hong Kong Limited take no responsibility for the contents of this announcement, make no representation as to its accuracy or completeness and expressly disclaim any liability whatsoever for any loss howsoever arising from or in reliance upon the whole or any part of the contents of this announcement.

FOSUN PHARMA

复星医药

上海復星醫藥（集團）股份有限公司

Shanghai Fosun Pharmaceutical (Group) Co., Ltd.*

(a joint stock limited company incorporated in the People's Republic of China with limited liability)

(Stock Code: 02196)

(1) RESIGNATION OF SUPERVISOR
(2) ELECTION OF EMPLOYEE SUPERVISOR
AND
(3) ELECTION OF THE CHAIRMAN OF THE SUPERVISORY COMMITTEE

The Company announces that with effect from 19 June 2024:

- (1) Ms. Ren Qian has resigned as an employee supervisor of the Company and the chairman of the Supervisory Committee;
- (2) Ms. Wang Lina has been appointed as an employee supervisor of the Company at the employee representatives meeting; and
- (3) Mr. Chen Bing has been elected as the chairman of the Supervisory Committee of the Company.

RESIGNATION OF EMPLOYEE SUPERVISOR

Shanghai Fosun Pharmaceutical (Group) Co., Ltd.* (the “**Company**”) hereby announces that the supervisory committee of the Company (the “**Supervisory Committee**”) recently has received a resignation letter from Ms. Ren Qian (“**Ms. Ren**”) who has tendered her resignation to the Supervisory Committee as an employee supervisor of the Company and the chairman of the Supervisory Committee as she has reached the age of retirement. Ms. Ren has ceased to be an employee supervisor of the Company and the chairman of the Supervisory Committee with effect from 19 June 2024.

Ms. Ren has confirmed that there is no disagreement between her and the Supervisory Committee and/or the Company during her term of office and there is no matter relating to her resignation that needs to be brought to the attention of the shareholders of the Company (the “**Shareholders**”).

The Company hereby expresses its gratitude to Ms. Ren for her valuable contribution during her term of office.

ELECTION OF EMPLOYEE SUPERVISOR

The Company is pleased to announce that pursuant to the articles of association of the Company, Ms. Wang Lina (“**Ms. Wang**”) has been appointed as an employee supervisor of the Company at the employee representatives meeting held on 19 June 2024, with a term of office commencing from 19 June 2024 until the expiration of the term of office of the ninth session of the Supervisory Committee. The biographical details of Ms. Wang are set out as follows:

Ms. Wang, aged 39, joined the Group in July 2007. She has served successively as management trainee, human resources specialist, compensation and benefits specialist, compensation and benefits supervisor, compensation and benefits manager, senior compensation and benefits manager, deputy director of remuneration and performance, director of remuneration and performance, assistant to the general manager (in charge of remuneration, performance and recruitment), deputy general manager and executive general manager of the human resources department of the Company from July 2007 to present. During that time, Ms. Wang has served successively as general manager of the human resources and administration department, assistant to the president and general manager of the human resources and administration department, vice president, chief human resources (CHO) and general manager of the human resources department of Shanghai Fosun Hospital Investment (Group) Co., Ltd.* (上海復星醫院投資(集團)有限公司), which has been renamed as Shanghai Fosun Health Technology (Group) Co., Ltd.* (上海復星健康科技(集團)有限公司) (“**Fosun Health**”), from January 2018 to present. Ms. Wang is currently a supervisor (employee supervisor) and executive general manager of the human resources department of the Company, as well as the vice president, CHO and general manager of the human resources department of Fosun Health, a subsidiary of the Company. Ms. Wang obtained her bachelor’s degree in economics from Shanghai Maritime University in July 2007 and her master’s degree in management from Renmin University of China in June 2013.

As at the date of this announcement, Ms. Wang has entered into a service contract with the Company as a supervisor. Ms. Wang will not receive any remuneration from the Company as a supervisor. The relevant supervisor service contract will not provide for a specific remuneration amount. The appointment of Ms. Wang as an employee supervisor of the Company will be effective from 19 June 2024 and end on the expiration of the term of the ninth session of the Supervisory Committee.

Ms. Wang has confirmed that, save as disclosed above, as at the date of this announcement, she does not have any relationship with any directors, other supervisors, senior management or substantial or controlling shareholders of the Company, and does not hold any other positions in the Company or any subsidiaries of the Company nor any directorships in public companies the securities of which are listed on any securities market in Hong Kong or overseas in the last three years. As at the date of this announcement, Ms. Wang holds 1,900 A shares of the Company in her own name, representing approximately 0.0001% of the total number of A shares of the Company in issue and approximately 0.0001% of the total number of shares of the Company in issue, respectively. Save as disclosed above, Ms. Wang does not have any interests or short positions in any shares, underlying shares or debentures of the Company within the meaning of Part XV of the Securities and Futures Ordinance.

Save as disclosed above, there is no other information required to be disclosed pursuant to Rule 13.51(2) of the Rules Governing the Listing of Securities on The Stock Exchange of Hong Kong Limited. There are no other matters concerning Ms. Wang that need to be brought to the attention of the Shareholders.

ELECTION OF THE CHAIRMAN OF THE SUPERVISORY COMMITTEE

The Company is pleased to announce that Mr. Chen Bing (“**Mr. Chen**”) was elected as the chairman of the Supervisory Committee of the Company, with a term of office commencing from 19 June 2024 until the expiration of the term of office of the ninth session of the Supervisory Committee. The biographical details of Mr. Chen are set out below:

Mr. Chen, aged 49, was appointed as the Company’s Supervisor on June 2023. Mr. Chen served at KPMG from September 1997 to August 2005. He served as a senior audit manager of MAZARS Shanghai Certified Public Accountants LLP* (上海瑪澤會計師事務所(普通合夥)) from April 2006 to August 2008 and a partner from August 2008 to July 2017. He served various positions including the joint general manager of the audit department, assistant to the president and senior assistant to the president of Fosun International Limited (stock code: 00656), a company listed on The Stock Exchange of Hong Kong Limited (the “**Hong Kong Stock Exchange**”), from July 2017 to December 2021. He also served as the vice president, the co-chief risk officer and the general manager of the audit department of Fosun International since January 2022. Mr. Chen is also a non-executive director of BabyTree Group (stock code: 01761), a company listed on the Hong Kong Stock Exchange, a director of Zhejiang Wansheng Co., Ltd.* (浙江萬盛股份有限公司) (stock code: 603010), a company listed on the Shanghai Stock Exchange, and concurrently holds directorships and supervisory positions in certain subsidiaries of Fosun International. Mr. Chen is currently a non-practicing member of the Chinese Institute of Certified Public Accountants and a member of Shanghai Institute of Certified Public Accountants. Mr. Chen obtained a bachelor’s degree in economics from Fudan University in July 1997.

As at the date of this announcement, Mr. Chen has entered into a service contract with the Company as a supervisor. Mr. Chen will not receive any remuneration from the Company as a supervisor. The relevant supervisor service contract will not provide for a specific remuneration amount.

Mr. Chen has confirmed that, save as disclosed above, as at the date of this announcement, he does not have any relationship with any directors, other supervisors, senior management or substantial or controlling shareholders of the Company, and does not hold any other positions in the Company or any subsidiaries of the Company nor any directorships in public companies the securities of which are listed on any securities market in Hong Kong or overseas in the last three years. As at the date of this announcement, Mr. Chen does not have any interests or short positions in any shares, underlying shares or debentures of the Company within the meaning of Part XV of the Securities and Futures Ordinance.

Save as disclosed above, there is no other information required to be disclosed pursuant to Rule 13.51(2) of the Rules Governing the Listing of Securities on The Stock Exchange of Hong Kong Limited. There are no other matters concerning Mr. Chen that need to be brought to the attention of the Shareholders.

By order of the Board
Shanghai Fosun Pharmaceutical (Group) Co., Ltd.*
Wu Yifang
Chairman

Shanghai, the PRC

19 June 2024

As at the date of this announcement, the executive directors of the Company are Mr. Wu Yifang, Mr. Wang Kexin, Ms. Guan Xiaohui and Mr. Wen Deyong; the non-executive directors of the Company are Mr. Chen Qiyu, Mr. Yao Fang, Mr. Xu Xiaoliang and Mr. Pan Donghui; and the independent non-executive directors of the Company are Ms. Li Ling, Mr. Tang Guliang, Mr. Wang Quandi and Mr. Yu Tze Shan Hailson.

* *For identification purposes only*